Evidence map›Paper›PMID 38082206›Full record

ArticleClinical rheumatology2024

The risk factors for uveitis among psoriatic arthritis patients: a population-based cohort study.

Nizar Hijazi, Tal Gazitt, Amir Haddad, Muna Elias, Sameer Kassem, Ilan Feldhamer, Arnon Dov Cohen, Shaul Sar, Oren Tomkins-Netzer, Walid Saliba and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Clinical rheumatology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Uveitis in Psoriatic Arthritis: A Comprehensive Review.European journal of rheumatology · 2025
    Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 2 countries.

Nizar HijaziDepartment of medicine A and Rheumatology Unit, Carmel Medical Center, Michal 7 St., 3436212, Haifa, Israel. nizar.m.h@me.com.ORCID http://orcid.org/0000-0002-7298-4673
Tal GazittRheumatology Unit, Carmel Medical Center, Haifa, Israel.ORCID https://orcid.org/0000-0001-8612-2698
Amir HaddadRheumatology Unit, Carmel Medical Center, Haifa, Israel.
Muna EliasRheumatology Unit, Carmel Medical Center, Haifa, Israel.
Sameer KassemDepartment of medicine A, Carmel Medical Center, Haifa, Israel.ORCID https://orcid.org/0000-0003-3588-0338
Ilan FeldhamerChief Physician's Office, Central Headquarters, Clalit Health Services, Tel Aviv, Israel.
Arnon Dov CohenChief Physician's Office, Central Headquarters, Clalit Health Services, Tel Aviv, Israel.
Shaul SarOpthalmology department, Carmel Medical Center, Haifa, Israel.
Oren Tomkins-NetzerOpthalmology department, Carmel Medical Center, Haifa, Israel.
Walid SalibaDepartment of Community Medicine and Epidemiology, Carmel Medical Center, Haifa, Israel.
Devy ZismanRheumatology Unit, Carmel Medical Center, Haifa, Israel.ORCID https://orcid.org/0000-0003-0523-2292
Carmel Medical Center · ILBen-Gurion University of the Negev · ILClalit Health Services · ILUniversity of Washington Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo assess the frequency of uveitis in patients with psoriatic arthritis (PsA) in the era of biologics and to identify risk factors associated with uveitis.

methodsA retrospective matched cohort study was conducted within the database of a large healthcare provider. Newly diagnosed 6147 adult PsA patients between 2005 and 2020 were matched by the index date of PsA diagnosis, age, sex, and ethnicity to 23,999 randomly selected controls. This cohort was used to examine the association between PsA and uveitis. An additional analysis was conducted within the PsA group to identify uveitis risk factors, using two analytic approaches: a retrospective cohort study and a nested case-control study.

resultsUveitis was diagnosed in 107 patients in the PsA group (1.7%) vs 187 (0.8%) patients in the control group (adjusted HR, 2.38, 95% CI 1.80-3.15, p<0.005) and was similar when the analysis was confined to patients without past uveitis. Uveitis was diagnosed more in females (2.1% vs 1.3%, HR 1.61, 95% CI 1.09-2.40, p<0.05), and was acute in all cases. Anterior uveitis was documented in 41.1% of the cases, 64.5% unilateral, and 9.3% bilateral. In the PsA group, using nested case control approach, only past uveitis [adjusted OR 136.4 (95% CI 27.38-679.88), p<0.005] and treatment with etanercept [adjusted OR 2.57 (95% CI 1.45-4.57), p=0.001] were independently associated with uveitis. Only one PsA patient with uveitis (out of 107) required systemic oral treatment with prednisone, while the rest of the patients were treated with topical glucocorticosteroids only.

conclusionPsA is associated with increased risk of uveitis. Past uveitis and treatment with etanercept were associated with higher risk of uveitis. Key Points • Psoriatic arthritis (PsA) is a major risk factor for uveitis with hazard ratio of 2.38 compared to healthy individuals without PsA. • Among PsA patients, the past event of uveitis and treatment with etanercept are risk factors for uveitis. • Uveitis in patients treated with biologics for their PsA requires topical therapy only in most of the cases.

Indexed as

Arthritis, PsoriaticBiological ProductsUveitisAdultCase-Control StudiesCohort StudiesEtanerceptFemaleHumansMaleRetrospective StudiesRisk FactorsBiological ProductsEtanerceptBiologicsPsoriatic arthritisRisk factorsUveitis

Identifiers

PMID38082206
OpenAlexW4389540725

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.